EdgePoint Investment Group Inc. Takes Position in Twist Bioscience Corporation $TWST

Key Points

• EdgePoint Investment Group Inc. acquired 1,113,210 shares of Twist Bioscience Corporation (NASDAQ:TWST), valued at approximately $43.7 million, increasing their ownership to about 1.86% of the company.
• Several other hedge funds, including Nuveen LLC and Citigroup Inc., have also increased their stakes in Twist Bioscience, highlighting growing institutional interest in the company.
• Twist Bioscience reported a quarterly loss of ($0.47) EPS, exceeding analysts' estimates, along with a revenue of $96.06 million, slightly above expectations.

EdgePoint Investment Group Inc. bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,113,210 shares of the company's stock, valued at approximately $43,705,000. EdgePoint Investment Group Inc. owned approximately 1.86% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in TWST. Nuveen LLC acquired a new position in Twist Bioscience in the 1st quarter worth approximately $31,960,000. ARK Investment Management LLC boosted its stake in Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after purchasing an additional 645,730 shares during the period. Citigroup Inc. boosted its stake in Twist Bioscience by 124.1% in the 1st quarter. Citigroup Inc. now owns 206,461 shares of the company's stock worth $8,106,000 after purchasing an additional 114,338 shares during the period. AQR Capital Management LLC boosted its stake in Twist Bioscience by 65.2% in the 1st quarter. AQR Capital Management LLC now owns 265,649 shares of the company's stock worth $10,429,000 after purchasing an additional 104,875 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Twist Bioscience in the 1st quarter worth approximately $3,977,000.

Analysts Set New Price Targets

TWST has been the subject of a number of recent analyst reports. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Stock Up 1.9%

TWST stock traded up $0.49 during midday trading on Monday, reaching $26.25. The company had a trading volume of 2,249,947 shares, compared to its average volume of 1,200,300. Twist Bioscience Corporation has a 1 year low of $24.28 and a 1 year high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.58 billion, a P/E ratio of -18.10 and a beta of 2.31. The company has a 50 day moving average of $31.74 and a two-hundred day moving average of $34.72.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the transaction, the chief executive officer owned 645,782 shares in the company, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 2,449 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at $3,951,157.35. This represents a 2.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,250 shares of company stock worth $193,852 in the last 90 days. 3.01% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.